What medicinal cannabis really costs in New Zealand

Cost is now the single biggest reason New Zealanders don't take up the medicinal cannabis scheme. Because Pharmac does not generally fund medicinal cannabis, patients usually pay the full price of both their consultations and their products out of pocket. Going in with clear expectations about money avoids nasty surprises.

There are two separate costs to think about: the service (consultations) and the product.

Consultation fees

These are the fees clinics charge for the doctor's time, and they vary widely between providers. Across the market, initial consultations commonly sit somewhere in the range of roughly $40 to $80 at the telehealth-style clinics, with follow-ups often cheaper (frequently in the $30–$50 range). Some clinics offer a free initial nurse eligibility call, and some run "pay only if approved" or subscription models. At the other end, a few in-person specialist services charge several hundred dollars for an initial consultation.

A few practical points:

• Follow-ups add up. Titration needs reviews, so budget for more than one appointment in the first few months.
• Concessions exist. Some clinics offer discounts for SuperGold, Community Services or Veteran cardholders.
• Your GP may be cheaper. If your own GP is willing to prescribe, ongoing reviews can cost much less than a clinic.

Always confirm current fees directly with the provider — published prices change.

Product costs

This is the larger and more variable expense, and it depends entirely on what you are prescribed and how much you use. As a rough guide drawn from recent NZ reporting:

• Dried flower has been quoted from around $10 per gram.
• Many patients spend on the order of $3–$7 per day depending on the product and dose.
• Monthly product spend commonly lands somewhere around $100–$300 for moderate use, and higher for high-strength products or larger doses.

The fully approved medicines sit at the expensive end: Sativex costs roughly $1,000 a month and is not Pharmac-funded for most people.

Why prices are falling

There is some genuinely good news. NZ's 2025 drug-trends data found prescribed cannabis has become cheaper and more available, with prices now described as comparable to illegal-market costs — a major shift from a few years ago. More products and more competition have driven this. (The flip side is a producer sector under real financial strain, which is why product availability can wobble.)

The funding exceptions

While general funding is off the table, a few narrow routes exist:

• Pharmac NPPA (Named Patient Pharmaceutical Assessment) — individual funding applications, but these are rarely granted. Of around 50 individual applications between 2021 and 2025, only nine were approved, generally for life-threatening or severe cases.
• ACC may cover treatment in some accident-related cases.
• WINZ / MSD support may help some low-income patients with costs, and certain clinics specifically work with WINZ funding.

These are exceptions, not the norm — but worth asking about if cost is a barrier.

Ways to keep costs down

While medicinal cannabis remains a self-funded medicine for most people, a few approaches can reduce the burden:

• Find the lowest effective dose. This is the single biggest lever on product cost. The "start low, go slow" approach isn't just about tolerability — a smaller effective dose is a cheaper one.
• Compare consultation fees. They vary widely between providers, and follow-up costs differ too. If your own GP will prescribe and review, that can be cheaper than a clinic over time.
• Ask about concessions for SuperGold, Community Services, Veteran or Health Care cards.
• Ask the pharmacy for the price of the specific product before it's dispensed, and ask your prescriber whether a comparable verified product is cheaper.
• Check eligibility for ACC or WINZ support if your situation fits.

None of these make the medicine free, but together they can meaningfully change the monthly total.

Why funding is limited

It's reasonable to ask why a legal medicine isn't funded. The short answer is evidence and process. Pharmac funds medicines based on assessed clinical and cost-effectiveness, and most medicinal cannabis products are unapproved medicines whose safety and efficacy haven't been formally assessed. Even Sativex, a fully approved medicine, was recommended against for funding by Pharmac's advisory committee back in 2015 and remains unfunded. Until the evidence base strengthens and products go through approval, broad funding is unlikely — which is why cost remains the scheme's hard ceiling.

Budgeting realistically

A sensible way to plan: assume you'll pay for an initial consultation, at least one or two follow-ups in the first few months, and a monthly product cost that could range from modest to a few hundred dollars depending on what works for you. Ask your prescriber for an estimate of the likely product and dose before you commit, and ask the pharmacy for the price of the specific product before it's dispensed.

The honest summary

Medicinal cannabis in New Zealand is a self-funded medicine for almost everyone. Costs have come down and continue to, but the absence of Pharmac funding means affordability remains a real barrier. Plan for both the service and the product, ask about concessions and exceptions, and make cost part of the conversation with your prescriber from the start.

Last reviewed 27 July 2026 — education, not medical advice. Sources: Pharmac — funding for medicinal cannabis; Massey NZ Drug Trends Survey 2025.